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ABSTRACT: Solid-phase peptide synthesis (SPPS) is used to create peptidomimetics in which one of the backbone amide C=O 
bonds is replaced by a four-membered oxetane ring. The oxetane containing dipeptide building blocks are made in three steps in 
solution, then integrated into peptide chains by conventional Fmoc SPPS. This methodology is used to make a range of peptides in 
high purity including backbone modified derivatives of the nonapeptide bradykinin and Met- and Leu-enkephalin. 
Despite resurgent interest in the use of peptides as drugs,1 their 
development is often hampered by their poor oral bioavailabil-
ity and short plasma half-lives. As a consequence, there is 
intense interest in the discovery of molecules that can mimic 
the structure and biological function of native peptides yet 
possess better drug-like properties.2-4 Independently, Shipman5 
and Carreira6 introduced a new type of peptide bond isostere 
in which the heterocyclic 3-aminooxetane unit was used as a 
replacement for one of the amide bonds (Figure 1).7 Several 
features of these oxetane modified peptides (OMPs) make 
them of particular interest as peptidomimetics. Firstly, deletion 
of one of the amide bonds can improve half-lives through in-
creased stability to proteases.6b Secondly, oxetanes are known 
to make excellent bioisosteric replacements for C=O bonds, 
and are commonly used in conventional, small molecule drug 
discovery.8 Thirdly, the 3-aminooxetane unit can act as both a 
H-bond donor and acceptor, supporting the types of non-
covalent interactions available to peptides.  Finally, conforma-
tional changes arising from removal of the double bond char-
acter of the peptide bond change the conformational bias of 
OMPs,5a opening up new areas of peptide structural space to 
explore.   
 
 
 
Figure 1. Oxetane Based Peptidomimetics 
 
To date, access to OMPs has been by way of solution-based 
methods.5,6 However, to study the impact of oxetane modifica-
tion on the structure and properties of larger, biologically im-
portant peptides, we turned to solid-phase peptide synthesis 
(SPPS).9  Our plan was to synthesize Fmoc-protected dipeptide 
building blocks such as 1, then integrate them into a growing 
peptide chain using automated SPPS techniques (Scheme 1). 
Here, we describe the successful development of this method-
ology, and use it to make a range of OMPs including novel 
enkephalin and bradykinin analogues.  
Initially, we sought a practical route to Fmoc-protected dipep-
tide building blocks in which the oxetane residue is based on 
glycine. Conjugate addition of the appropriate amino ester, 
made from 2a-i by initial Fmoc cleavage, to 3-
(nitromethylene)oxetane readily gave the addition products 
3a-i (Table 1).5 Raney Ni reduction of 3a-i in the presence of 
FmocOSu provided 4a-i in good yields.6 A range of protected 
side chain types were introduced namely: acidic, basic, polar 
and non-polar.   
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 Scheme 1. SPPS Route to Oxetane Modified Peptides 
 
The last step prior to SPPS was selective removal of the ester 
group (R1); a transformation that required considerable opti-
mization to safeguard the Fmoc and side chain protecting 
groups. Initially, phenylalanine derivatives containing methyl 
(4a), benzyl (4b), 2,4-dimethoxybenzyl (4c) and 2-
phenylisopropyl (cumyl, 4d) esters were studied (Table 1, 
entries 1-4). Cleavage of the methyl ester from 4a using Li-
OH-THF/H2O led to unwanted N-Fmoc cleavage. Other condi-
tions reported to leave Fmoc groups unscathed such as 
Me3SnOH10 and NaOH/CaCl211 also proved unsuccessful. 
Hydrogenolysis of benzyl ester 4b (H2, 10% Pd/C, MeOH) did 
provide the corresponding carboxylic acid in an encouraging 
50% yield. However, optimization of this transformation and 
its extension to derivatives containing other side chains proved 
impractical.12 Poor results were also observed in the attempted 
removal of the 2,4-dimethoxybenzyl group from 4c using mild 
acid (1% TFA-CH2Cl2, anisole).13 Much better outcomes were 
achieved with cumyl ester 4d which was quantitively depro-
tected upon treatment with 2% TFA in CH2Cl2 for 1.5 h.14a  On 
this basis, we focused our subsequent efforts on cumyl esters 
4d-i. From a practical standpoint, these derivatives proved 
attractive as they were bench stable, crystalline solids. Indeed, 
it proved most convenient to store the building blocks as the 
cumyl esters, then reveal the carboxylic acid using 2% TFA in 
CH2Cl2 immediately prior to SPPS.  These materials were 
produced on up to a 3 mmol scale (see Supporting Infor-
mation). Moreover, the starting cumyl esters 2d-i were easily 
made from the corresponding Fmoc-protected amino acids by 
reaction with 2-phenylisopropyl-trichloroacetimidate (see 
Supporting Information).14  
Initially, the use of the building blocks in solution-phase cou-
plings was established (Scheme 2). Cleavage of the cumyl 
ester from 4e followed by coupling with L-phenylalanine tert-
butyl ester with O-(1H-6-chlorobenzotriazole-1-yl)-1,1,3,3-
tetramethyluronium hexafluorophosphate (HCTU) and diiso-
propylethylamine (DIPEA) gave (S,S)-5a in excellent yield.  
Using D-phenylalanine tert-butyl ester in the same sequence 
provided (S,R)-5b. Analysis by 1H NMR confirmed that no 
detectable epimerization arose during these couplings (see 
Supporting Information). Subjecting 4h bearing a Boc-
protected lysine to the same cleavage/coupling conditions 
cleanly gave 6 without evidence of side chain deprotection. 
Additionally, 4d was converted to 7 by chain extension at the 
N-terminus.  In this transformation, no products derived from 
acylation of the secondary amine of the 3-aminooxetane unit 
were isolated despite the use of 4 equiv. of the coupling part-
ners. This observation encouraged us to explore SPPS without 
recourse to protection of the oxetane nitrogen atom.   
Scheme 2. Selective Cumyl Ester Deprotection and Solu-
tion Phase Couplings 
 
Next, we examined the use of 4d-i in SPPS. These experi-
ments were conducted on a 0.1 mmol scale in a Biotage Alstra 
microwave synthesizer using preloaded chlorotrityl resin and 
HCTU activation (for full details, see Supporting Infor-
mation).  Initially, six tetrapeptides 8-13 were synthesized 
using each of the building blocks, 4d-i (Table 2, entries 1-6).  
Two equivalents of the building blocks were used, with a pre-
treatment with 2% TFA in CH2Cl2 under anhydrous conditions 
to cleave the cumyl ester, immediately prior to coupling.  
Standard conditions for Fmoc removal (20% piperidine, 0.1 M 
Oxyma pure, DMF),15 coupling [Fmoc-Trp-OH, HCTU, 
DIPEA, DMF] and resin cleavage/deprotection 
[TFA/triisopropylsilane(TIS)/CH2Cl2 (70:20:10, v/v/v)] were 
adopted. After reverse-phase HPLC, these tetrapeptides were 
isolated in high purity and acceptable yields. Pleasingly, the 
oxetane did not undergo ring opening under the harsh acidic 
conditions required for release from the resin and concomitant 
side chain deprotection. Encouraged by these results, we pre-
pared oxetane modified analogues of biologically relevant 
peptides. First, we made 14 and 15, analogues of opioid-
binding Met- and Leu-enkephalin respectively, in which the 
central glycine was replaced (Table 2, entries 7 and 8).16 Simi-
larly, 16 was produced in good yield and excellent purity as an 
analogue of the vasodilator bradykinin. No erosion in peptide 
yield or purity was seen in the preparation of this nonapeptide, 
indicating that the 3-aminooxetane residue is well tolerated in 
repetitive rounds of coupling/Fmoc deprotection.     
In summary, we have developed a practical route to oxetane 
modified peptides using solid-phase peptide synthesis tech-
niques. Key findings include: (i) that cumyl-protected dipep-
tide building blocks 4d-i are easily made in three simple steps 
and the ester selectively cleaved with 2% TFA in CH2Cl2; (ii) 
that efficient amide couplings using these building blocks can 
be achieved in solution or on solid-phase without protecting 
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65%
 the secondary amine of the 3-aminooxetane residue; (iii) that 
oxetane containing peptides (up to 9 amino acids) can be pro-
duced in high purity using conventional SPPS methods for 
coupling, resin cleavage, deprotection and purification sug-
gesting the broad applicability of this modification in peptide 
science. Current work is focused on using this new methodol-
ogy to produce a variety of OMPs so that the impact of this 
backbone modification on the secondary structure, physico-
chemical and biological properties of the peptides can be sys-
tematically explored.  
Table 1.  Synthesis of Oxetane Containing Dipeptide Building Blocks  
 
entry  product 
(step 1) 
structure yield (%)b product 
(step 2) 
structure yield (%)b  
1  3a 
 
54c,d 4a 
 
87f 
2  3b 
 
73c,e 4b 
 
69f 
3  3c 
 
61 4c 
 
63f 
4  3d  
 
57 4d  
 
58 
5 3e 
 
55 4e 
 
76 
6 3f 
 
54 4f 
 
78 
7 3g 
 
40 4g 
 
77 
8 3h 
 
56 4h 
 
71 
9 3i 
 
56c 4i 
 
50 
a Prepared in-situ from oxetan-3-one and nitromethane (see Supporting Information). b After column chromatography. c Made directly from 
α-amino ester without Fmoc deprotection. d Ref 5b.  e Ref 5a.  f Using 1.2 equiv FmocOSu. 
  
 
 
 
 
 
 
 
 
 
FmocHN
O
OR1
R
O2N
H
N
OR1
O
O R
1. 50% Et2NH, CH2Cl2
2.
2a-i 3a-i
O
O2N CH2Cl2
FmocOSu (2 equiv)
NaHCO3, RaNi, H2
THF, RT
FmocHN
H
N
O R
4a-i
O
OR1
a
step 1 step 2
O2N
H
N
OMe
O
O Ph
FmocHN
H
N
OMe
O
O Ph
O2N
H
N
OBn
O
O Ph
FmocHN
H
N
OBn
O
O Ph
O2N
H
N
O
O
O Ph
OMe
OMe
FmocHN
H
N
O
O
O Ph
OMe
OMe
O2N
H
N
O
O
Ph
O Ph
FmocHN
H
N
O
O
Ph
O Ph
O2N
H
N
O
O
Ph
O
FmocHN
H
N
O
O
Ph
O
O2N
H
N
O
O
Ph
O OtBu
FmocHN
H
N
O
O
Ph
O OtBu
O2N
H
N
O
O
Ph
O CO2tBu
FmocHN
H
N
O
O
Ph
O CO2tBu
O2N
H
N
O
O
Ph
O NHBoc
FmocHN
H
N
O
O
Ph
O NHBoc
O2N
N
O O O Ph
FmocHN
N
O O O Ph
   
Table 2.  Solid-Phase Synthesis of Oxetane Modified Peptides 
 
entry building  
blocka 
peptide  
sequenced 
purity  
(%)e 
mass, mg 
 (yield, %)  
peptide  
content (%)f 
HRMS 
 calculated                      observed 
1 4d W-GOx-F-A, 8 89 10.7 (21) 75 508.2554 [M+H]+ 508.2531 [M+H]+ 
2 4e W-GOx-V-A, 9 93 8.4 (18) 55 460.2554 [M+H]+ 460.2544 [M+H]+ 
3 4f W-GOx-S-A, 10 81 (90)g 12.0 (27) 73 448.2191 [M+H]+ 448.2190 [M+H]+ 
4 4g W-GOx-D-A, 11 81 (91)g 13.7 (29) 75 476.2140 [M+H]+ 476.2129 [M+H]+ 
5 4h W-GOx-K-A, 12 93 5.0 (10) 48 489.2820 [M+H]+ 489.2818 [M+H]+ 
6 4i W-GOx-P-A, 13 94 14.6 (32) 62 480.2217 [M+Na]+ 480.2213 [M+Na]+ 
7 4d Y-G-GOx-F-M, 14 91 17.0 (28) 81 602.2643 [M+H]+ 602.2659 [M+H]+ 
8 4d Y-G-GOx-F-L, 15 91 16.4 (28) 79 584.3079 [M+H]+ 584.3056 [M+H]+ 
9 4d R-P-P-GOx-F-S-P-F-R, 16 94 25.3 (46) 63 544.8036 [M+2H]2+ 544.8014 [M+2H]2+ 
a Treated with 2% TFA in CH2Cl2 for 2 h to reveal the free carboxylic acid from 4d-i prior to coupling with the resin-bound peptide. b 30 s, 
then 3 min with fresh reagents. c All couplings performed at 75 °C for 10 min except arginine (60 min at RT, then 5 min at 75 °C, repeated 
with fresh reagents). d Italized residues derived from the oxetane containing dipeptide building block. e By reverse-phase HPLC (see Sup-
porting Information). f Determined by UV spectroscopy (at 280 nm) except 16 (at 214 nm). g Improved to >90% by second purification.  
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